




T1Detect Update

Anastasia Albanese-O'Neill, PhD, CPNP-PC, CDCES
Associate Vice President
T1D Education and Clinical Implementation

JDRF Research Priorities




**Global Universal
Screening**



**Disease Modifying
Therapies**



Cell Therapies




Improving Lives



**Training of
Researchers and Clinicians**

JDRF's T1Detect Program

**An Education
and Awareness
Program on T1D
Risk Screening
and Monitoring**



(Rebranded in 2022)

T1Detect ≠ Mail Order Kit

**Learn
About
Screening**



**Get
Screened**



**Follow
Up and
Monitoring**



T1Detect Goals

- Reduce incidence of diabetic ketoacidosis (DKA) at diagnosis**
- Identify individuals for T1D research studies**
- Expand access to FDA approved therapies**



JDRF's T1Detect Strategy Relies on a Multilevel Approach



Educate Healthcare Professionals



Educate JDRF Staff, Volunteers, and the T1D Community



Expand Clinical Pilots to Diverse Populations



Enhance Online, Digital, and Print Resources



Drive Consensus Monitoring Guidelines

All of these tactics are designed to support expanded and equitable access to screening, empower constituents, encourage clinical adoption, and accelerate global development of disease modifying therapies.

HCP Education

>2000

Healthcare Professionals received accredited education

- Conference-based strategy
- Specialty focused

>3000

Healthcare Professionals will receive accredited education


- Clinic-based strategy
- Actionable
- Primary care focus

Elements

- Accredited offerings
- Virtual and on demand
- Primary care Conferences: Screening and Staging
- Specialty care: Monitoring
- Patient Facing Materials
- Provider Toolkit

Community Education

If you or someone in your family has T1D, what is the risk of other family members getting diagnosed with T1D?



■ Correct Answer ■ Incorrect Answer

>3000

Staff, volunteers and constituents participated T1D Risk Screening Education

T1Detect Pilot Clinics

- Improve access to screening among underrepresented groups
- Demonstrate feasibility, acceptability and efficacy of T1D risk screening and monitoring in the clinical setting
- Explore diverse setting, with emphasis on primary care
- Bridge funding for clinical implementation



“Diversity [in screening] ... is stagnant over past 15+ years despite increasing diversification of who is being diagnosed with T1D.”

Pilot Clinics



University Hospital affiliated with Rutgers University in Newark, NJ


- Community based approach
- FTE for staff and patient navigator
- >600 individuals screened
- <5% of participants NHW
- Developing SOPs for monitoring IAb+ individuals

Activated 2 pilot sites end of FY22

Contracted with 37 additional sites in FY23

Exploring 5 additional sites

Regionalized funding support



Consensus Monitoring Guidance:

“Consensus guidance for monitoring persons with islet autoantibody-positive pre-Stage 3 type 1 diabetes”





Consensus Monitoring Guidance Timeline

	Feb	Mar	Apr	May	Jun	Jul	Aug	Sept	Oct	Nov	Dec
Working Group Kick Off Meeting											
Working Groups Meet											
Initial Draft, Scientific Writer											
Working Group Comment Period											
Revisions, Scientific Writer											
Working Group Meeting (ADA)											
Final Revisions, Scientific Writer											
Feedback from Partner Societies											
Final Draft Submitted for Publication											

T1Detect: Communication Strategy

- JDRF has reached over **10 million** people through our integrated marketing approach.
- RFP launched to refine **core messaging**, build **social media assets**, develop **earned media** strategy
- **Storytelling** based on JDRF community experiences
- **Paradigm shift** in how we think about type 1 diabetes





Thank you for your partnership!

aaoneill@jdrf.org